What is Derma Sensor?
DermaSensor Inc. operates at the intersection of health technology and artificial intelligence, focusing on the development of non-invasive, handheld tools designed to assist primary care providers in the detection of skin cancer. By leveraging spectroscopy and machine learning, the device provides rapid, objective evaluations of skin lesions, effectively democratizing access to high-quality dermatological screening. Currently CE Marked and available in select international markets like Australia and New Zealand, the company is addressing a significant unmet need in the healthcare sector by reducing the reliance on specialist referrals for routine checks, thereby optimizing patient outcomes and lowering systemic healthcare expenditures.
How much funding has Derma Sensor raised?
Derma Sensor has raised a total of $21.8M across 4 funding rounds:
Debt
$150K
Series A
$11.5M
Debt
$162K
Other Financing Round
$10M
Debt (2020): $150K with participation from PPP
Series A (2020): $11.5M led by David Matlin, SternAegis Ventures, Chris Dewey, and Dr. Maurice R. Ferre
Debt (2021): $162K supported by PPP
Other Financing Round (2022): $10M featuring Ceros Capital Markets
Key Investors in Derma Sensor
Ceros Capital Markets
Ceros Capital Markets is a global investing platform that specializes in fundraising for MedTech and Biotech companies, focusing on disruptive technologies in medical devices, robotics, and digital health.
SternAegis Ventures
SternAegis Ventures specializes in principal investing, investment banking, merchant banking, and strategic consulting services, aiming to accelerate growth and unlock value for qualified small businesses.
David Matlin
An individual investor participating in the strategic growth of the company, providing capital and industry expertise to support the development of non-invasive diagnostic technologies.
What's next for Derma Sensor?
With the support of its latest strategic financing, DermaSensor is poised to accelerate its commercialization efforts and navigate the complex regulatory pathways required for broader global market entry. The company's focus will likely shift toward scaling its manufacturing capabilities and expanding its clinical evidence base to support future regulatory submissions in additional jurisdictions. As the firm continues to refine its diagnostic algorithms, it remains focused on its core objective: transforming the standard of care for skin cancer detection by empowering primary care physicians with accessible, data-driven diagnostic tools that enhance clinical efficiency and patient safety.
See full Derma Sensor company page
